|
1
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mulshine JL and Sullivan DC: Clinical
practice. Lung cancer screening. N Engl J Med. 352:2714–2720. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sax SN, Zu K and Goodman JE: Air pollution
and lung cancer in Europe. Lancet Oncol. 14:e439–e440. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taniwaki M, Daigo Y, Ishikawa N, Takano A,
Tsunoda T, Yasui W, Inai K, Kohno N and Nakamura Y: Gene expression
profiles of small-cell lung cancers: Molecular signatures of lung
cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
7
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W,
Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell
lung cancer and promotes lung cancer cell growth in vitro and in
vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
|
|
10
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression
of microRNA-129-2 suppresses cell aggressiveness by inhibiting high
mobility group box 1 in human hepatocellular carcinoma. Oncotarget.
7:36909–36923. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rothschild SI, Tschan MP, Jaggi R, Fey MF,
Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is
deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang H, Liu X, Wang Z, She X, Zeng X, Deng
M, Liao Q, Guo X, Wang R, Li X, et al: Interaction of hsa-miR-381
and glioma suppressor LRRC4 is involved in glioma growth. Brain
Res. 1390:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang Y, Zhao Q, Fan L, Zhang Z, Tan B,
Liu Y and Li Y: Down-regulation of MicroRNA-381 promotes cell
proliferation and invasion in colon cancer through up-regulation of
LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Q, Zhao S, Pang X and Chi B:
MicroRNA-381 suppresses cell growth and invasion by targeting the
liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep.
35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xue Y, Xu W, Zhao W, Wang W, Zhang D and
Wu P: miR-381 inhibited breast cancer cells proliferation,
epithelial-to-mesenchymal transition and metastasis by targeting
CXCR4. Biomed Pharmacother. 86:426–433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia B, Li H, Yang S, Liu T and Lou G:
MiR-381 inhibits epithelial ovarian cancer malignancy via YY1
suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W
and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer
by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Zhao C, Yu Z, Chen J, She X, Li P,
Liu C, Zhang Y, Feng J, Fu H, et al: Low expression of miR-381 is a
favorite prognosis factor and enhances the chemosensitivity of
osteosarcoma. Oncotarget. 7:68585–68596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen T, Ren H, Thakur A, Yang T, Li Y,
Zhang S, Wang T and Chen M: miR-382 inhibits tumor progression by
targeting SETD8 in non-small cell lung cancer. Biomed Pharmacother.
86:248–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu W, Xiao P, Wu H, Wang L, Kong D and Yu
F: MicroRNA-98 plays a suppressive role in non-small cell lung
cancer through inhibition of SALL4 protein expression. Oncol Res.
Nov 17–2016.(Epub ahead of print).
|
|
23
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer
cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J
Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang H, Wang Z, Liu Q, Liu X, Wu M and Li
G: Disturbing miR-182 and −381 inhibits BRD7 transcription and
glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He X, Wei Y, Wang Y, Liu L, Wang W and Li
N: MiR-381 functions as a tumor suppressor in colorectal cancer by
targeting Twist1. Onco Targets Ther. 9:1231–1239. 2016.PubMed/NCBI
|
|
26
|
Wang Z, Yang J, Xu G, Wang W, Liu C, Yang
H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis
sensitizes glioblastoma cells to temozolomide by regulating
stemness factors and multidrug resistance factors. Oncotarget.
6:3147–3164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chand AL, Pathirage N, Lazarus K, Chu S,
Drummond AE, Fuller PJ and Clyne CD: Liver receptor homologue-1
expression in ovarian epithelial and granulosa cell tumours.
Steroids. 78:700–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nadolny C and Dong X: Liver receptor
homolog-1 (LRH-1): A potential therapeutic target for cancer.
Cancer Biol Ther. 16:997–1004. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fayard E, Auwerx J and Schoonjans K:
LRH-1: An orphan nuclear receptor involved in development,
metabolism and steroidogenesis. Trends Cell Biol. 14:250–260. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang W, Tian Y, Jiang S, Liu S, Zhao X
and Tian D: MicroRNA-376c suppresses non-small-cell lung cancer
cell growth and invasion by targeting LRH-1-mediated Wnt signaling
pathway. Biochem Biophys Res Commun. 473:980–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
